Recombinant Bivalent Human Papillomavirus Vaccine (Types 16/18) (HPV-2) was pre-qualified by World Health Organization in August 2024
2023
SARS-CoV-2 mRNA Vaccine (Omicron XBB.1.5) received Emergency Use Authorization by Chinese NMPA
2022
In 2022, Walvax's Recombinant Bivalent Human Papillomavirus Vaccine (Types 16/18) (HPV-2) was launched. SARS-CoV-2 mRNA vaccine (AWcorna) was authorized under Indonesia EUA. 13-valent Pneumococcal Polysaccharide Conjugate Vaccine was Exported to Morocco and included in the National Immunization Program.
2020
In 2020, at the COVID-19 outbreak, Walvax has led the efforts in developing 2 vaccinology for the SARS-CoV-2 virus, which are mRNA vaccinology and recombinant subunit vaccinology.
2019
In 2019, Walvax identified 10-year development strategy which is to achieve internationalization, Industry 4.0 and import substitution. 13-valent Pneumococcal Polysaccharide Conjugate Vaccine was launched. Walvax received USD2.5 million from Bill & Melinda Gates Foundation to expedite the development of HPV9 vaccines.
2018
In 2018, Group A and C Meningococcal Polysaccharide Vaccine was Exported to Egypt and included in the National Immunization Program.
2017
In 2017, Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine were launched in China, and Group ACYW135 Meningococcal Polysaccharide Vaccine was exported to Indonesia.
2015
In 2015, Walvax built partnership with Bill & Melinda Gates Foundation.
2012
In 2012, Group A and C Meningococcal Polysaccharide Vaccine and Group ACYW135 Meningococcal Polysaccharide Vaccine were launched, and Haemophilus Influenzae Type b Conjugate Vaccine was officially exported to the Philippines.
2010
In 2010, Walvax was listed on the Growth Enterprise Market (GEM) of Shenzhen Stock Exchange (SZSE). The stock name is abbreviated to “Walvax Biotechnology”, with the stock code of “300142”.
2009
In 2009, Group A and Group C Meningococcal Conjugate Vaccine was launched.
2007
In 2007, Walvax’s first independently developed and industrialized vaccine product, Haemophilus Influenzae Type b Conjugate Vaccine, was launched.
2004
In 2004, Walvax commenced the construction of Yuxi Manufacturing Base.